deltatrials
Terminated OBSERVATIONAL NCT04357717

ExoDx Prostate Evaluation in Prior Negative Prostate Biopsy Setting

Clinical Evaluation of ExoDx™ Prostate (IntelliScore) in Men With Prior Negative Prostate Biopsy Presenting for a Repeat Biopsy

Sponsor: Exosome Diagnostics, Inc.

Interventions ExoDx Prostate
Updated 8 times since 2020 Last updated: Mar 17, 2022 Started: Mar 15, 2020 Primary completion: Sep 1, 2021 Completion: Sep 1, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

project reprioritization

A observational or N/A phase clinical study on Prostate Cancer, this trial is terminated or withdrawn. The trial is conducted by Exosome Diagnostics, Inc. and has accumulated 8 data snapshots since 2020. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~May 2020 – ~Jul 2020 · 2 months · monthly snapshot~Jul 2020 – ~Jan 2021 · 6 months · monthly snapshotRecruiting~Jan 2021 – ~Oct 2021 · 9 months · monthly snapshotRecruiting~Oct 2021 – ~Apr 2022 · 6 months · monthly snapshotRecruiting~Apr 2022 – ~Jul 2024 · 27 months · monthly snapshotTerminated~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotTerminated~Sep 2025 – present · 10 months · monthly snapshotTerminated

Change History

8 versions recorded
  1. Sep 2025 — Present [monthly]

    Terminated

  2. Sep 2024 — Sep 2025 [monthly]

    Terminated

  3. Jul 2024 — Sep 2024 [monthly]

    Terminated

  4. Apr 2022 — Jul 2024 [monthly]

    Terminated

    Status: RecruitingTerminated

  5. Oct 2021 — Apr 2022 [monthly]

    Recruiting

Show 3 earlier versions
  1. Jan 2021 — Oct 2021 [monthly]

    Recruiting

  2. Jul 2020 — Jan 2021 [monthly]

    Recruiting

  3. May 2020 — Jul 2020 [monthly]

    Recruiting

    First recorded

Mar 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Exosome Diagnostics, Inc.
Data source: Exosome Diagnostics, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .